(firstQuint)Safety and Immune Response Study of an Investigational Pneumococcal Vaccine.

.

 The study is open and subjects will receive two vaccine doses of GSK Biologicals' 11 PCV vaccine.

 Five blood samples will be taken: prior to and one month after each vaccine dose, and 2 weeks after dose 2.

.

 Safety and Immune Response Study of an Investigational Pneumococcal Vaccine.

@highlight

The purpose of this study is to evaluate the safety and immunogenicity of two doses of GSK Biologicals' 11 PCV vaccine when given to healthy subjects aged 18 to 40 years .

